MedTrace Logo

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

NCT02559895 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 898

Last updated 2020-05-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.

Conditions

  • Migraine Disorders

Interventions

DRUG

ALD403

DRUG

Placebo

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Tim Whitaker, MD · Alder Biopharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-02-28
Completion
2017-12-31

Countries

  • United States
  • Georgia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559895 on ClinicalTrials.gov